Search company, investor...
August Bioservices company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series A - II | Alive

Total Raised


Last Raised

$23.6M | 1 yr ago

About August Bioservices

August Bioservices is a team of highly experienced scientists and professionals, providing a comprehensive service offering to advance drug discovery, pharmaceutical development, and clinical manufacturing for the pharmaceutical and biotechnology industries. August Bioservices is positioned to support individual projects or to serve as an extension of its customers’ development teams.

August Bioservices Headquarters Location

1845 Elm Hill Pike

Nashville, Tennessee, 37210,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest August Bioservices News

August Bioservices Closes $23.6 Million Series A Extension to Expand U.S. Biopharma Manufacturing Capabilities

May 29, 2021

Polaris Partners joins Oak HC/FT as Key Investors NASHVILLE, Tenn., May 28, 2021-- August Bioservices,LLC, a contract development and manufacturing organization (CDMO) providing drug discovery, development, and pharmaceutical manufacturing services, closed a $23.6 million Series A extension, led by Polaris Partners, who joined existing investor Oak HC/FT. The proceeds will go toward expanding August’s manufacturing capacity and capabilities to advance the technology platforms needed to support production of sterile injectable medications. As part of the financing, Brian Chee, Managing Partner of Polaris Partners, joined the August Bioservices’ board as a Director. August Bioservices is headquartered in Nashville, TN, and is a high-tech, growth-focused, and innovative company that plays a crucial role in the global pharmaceutical industry supply chain. August Bioservices partners with biopharmaceutical and biotech companies to provide a wide array of services that help to accelerate the advancement of novel therapeutics along the drug development pathway. August’s service portfolio includes cGMP non-sterile and bulk manufacturing, aseptic fill and finish, labeling and related services. The company also provides drug formulation, process design and scale-up, analytical and stability testing, and research services that feature target validation, characterization and assay development, protein engineering and cell-line development. “Today the CDMO market remains fragmented, and manufacturing capacity in the US has not kept pace with the surging investor interest in early-stage biotechnology. The need to expand domestic manufacturing capacity has been underscored by the pandemic and international trade disputes,” said Darren Carroll of Polaris Partners, who joined the August Bioservices board as an observer. “We see significant potential in August’s commitment to meeting the manufacturing quality standards required by world-class biopharmaceutical companies.” In November 2020, August announced a planned $64.7 million investment to expand its Nashville manufacturing operations, which will add 180 jobs over five years. The first expansion project, which will focus on renovating August’s existing facility, includes the addition of development and manufacturing capabilities for liquid and lyophilized vials, prefilled syringes, IV bags and terminal sterilization. This renovation is expected to be completed in late 2021. The second expansion project will add a new state-of-the-art, high-speed manufacturing facility, adjacent to the existing building, which will create one contiguous campus for drug discovery, development and manufacturing in Nashville. “We are delighted to welcome Polaris Partners to the August Bioservices team,” commented Jenn Adams, CEO of August Bioservices. “Polaris shares our focus on offering the highest quality research, development and manufacturing services to our customers as they work to provide lifesaving medications to patients who need them. We look forward to a long and productive partnership as we deploy resources toward serving the global biopharmaceutical industry with increasing impact.” About August Bioservices Headquartered in Nashville, TN, August Bioservices, LLC is a high-tech, growth-focused, and innovative provider of Contract Research, Development and Manufacturing services, that plays a crucial role in the global pharmaceutical industry supply chain. For the biotech and pharma companies it serves, August is a US-based outsourcing partner with state-of-the-art instrumentation, industry-leading technical expertise, and decades of finished dose pharmaceutical manufacturing experience. For more information about August’s full line of services: For more information about August’s specialized services: Contact:

August Bioservices Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

August Bioservices Rank

  • When was August Bioservices founded?

    August Bioservices was founded in 2017.

  • Where is August Bioservices's headquarters?

    August Bioservices's headquarters is located at 1845 Elm Hill Pike, Nashville.

  • What is August Bioservices's latest funding round?

    August Bioservices's latest funding round is Series A - II.

  • How much did August Bioservices raise?

    August Bioservices raised a total of $23.6M.

  • Who are the investors of August Bioservices?

    Investors of August Bioservices include Polaris Partners and Oak HC/FT Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.